Multimodal Diagnostic Imaging for Hyperacute Stroke
AJNR 36:2206-2213, Vo, K.D.,et al, 2015
MRI-Based and CT-Based Thrombolytic Therapy in Acute Stroke Within and Beyond Established Time Windows
Stroke 38:2640-2645, Schellinger,P.D.,et al, 2007
Thrombolysis for Acute Ischemic Stroke in the Unwitnessed or Extended Therapeutic Time Window
Neurol 94:e1241-e1248, Tsivgoulis, G.,et al, 2020
Intravenous Alteplase for Stroke with Unknown Time of Onset Guided by Advanced Imaging:Systematic Review and Meta-Analysis of Individual Patient Data
Lancet 396:1574-1585, Thomalla,G.,et al, 2020
Multimodal CT or MRI for IV thrombolysis in ischemic stroke with unknown time of onset
Neurol 95:e2954-e2964, Macha, K.,et al, 2020
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
NEJM 380:1795-1803,1865, Ma, H.,et al, 2019
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
NEJM 378:11-22,81, Nogueira, R.G.,et al, 2018
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
NEJM 379:611-622, 682, Thomalla, G.,et al, 2018
Intravenous Thrombolysis in Unwitnessed Stroke Onset: MR WITNESS Trial Results
Ann Neurol 83:980-993, Schwamm, L.H.,et al, 2018
Endovascular Treatment for Patients with Acute Stroke Who Have a Large Ischemic Core and Large Mismatch Imaging Profile
JAMA Neurol 74:34-40, Rebello, L.C.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Computed Tomographic Perfusion to Predict Response to Recanalization in Ischemic Stroke
Ann Neurol 81:849-856, Lansberg, M.G.,et al, 2017
Favorable Bridging Therapy Based on DWI-FLAIR Mismatch in Patients with Unclear-Onset Stroke
AJNR 37:88-93, Mourand, I.,et al, 2016
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
NEJM 372:11-20,78, Berkhemer, O.A.,et al, 2015
Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
NEJM 372:1019-1030, Goyal, M.,et al, 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:2285-2295,2347, Saver, J.L.,et al, 2015
Thrombectomy within 8 hours after Symptom Onset in Ischemic Stroke
NEJM 372:2296-2306,2347, Jovin, T.G.,et al, 2015
Computed Tomographic Angiography or Magnetic Resonance Angiography for Detection of Intracranial Vascular Malformations in Patients with Intracerebral Hemorrhage
Stroke 46:e2-e3, Josephson, C.B.,et al, 2014
A Trial of Imaging Selection and Endovascular Treatment for Ischemic Stroke
NEJM 368:914-923,952, Kidwell, C.S.,et al, 2013
Endovascular Therapy after Intravenous t-PA versus t-PA Alone for Stroke
NEJM 368:893-903,952, Broderick, J.P.,et al, 2013
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Effect of Glatiramer Acetate on Conversion to Clinically Definite Multiple Sclerosis in Patients with Clinically Isolated Syndrome (PreCISe study): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 374:1503-1511, 1475, Martinelli,G.,et al, 2009
Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young
Stroke 39:2644-2691, Roach,E.S.,et al., 2008
Identification of the Penumbra and Infarct Core on Hyperacute Noncontrast and Perfusion CT
Neurol 68:730-736,717, Parsons,M.W.,et al, 2007
Magnetic Resonance Perfusion Diffusion Mismatch and Thrombolysis in Acute Ischaemic Stroke: A Systematic Review of the Evidence to Date
JNNP 78:485-491,443, Kane,I.,et al, 2007
Is IV Tissue Plasminogen Activator Beneficial in Patients With Hyperdense Artery Sign?
Neurol 66:1171-1174, Qureshi,A.I.,et al, 2006
Using the Baseline CT Scan to Select Acute Stroke Patients for IV-IA Therapy
AJNR 27:1612-1616, Hill,M.E.,et al, 2006
Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window Using Multimodal Transcranial Doppler/MRI Selection Protocol
Stroke 36:602-606, Ribo,M., et al, 2005
Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch on MRI Can Now be Used to Select Patients for Recombinant Tissue Plasminogen Activator Beyond 3 Hours
Stroke 36:1099-1100, 1100, Zivin,J.A., 2005
Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch on MRI Can Now Be Used to Select Patients for Recombinant Tissue Plasminogen Activator Beyond 3 Hours
Stroke 36:1098-1099,1100, Schellinger,P.D. &Fiebach,J.B., 2005
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase
Stroke 36:66-73, Hacke,W.,et al, 2005
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Tenecteplase for Stroke - Opening the Window?
NEJM 390:760-761, Leifer,D.,, 2024
Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients with Standard Surgical Risk
JAMA Neurol 80:437-444,435, Liang,P.,et al, 2023
Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion
NEJM 388:2025-2095, Zi,W.,et al, 2023
Endovascular Therapy Versus Medical Treatment for Symptomatic Intracranial Artery Stenosis
Stroke 54:e305-e306, Luo,J.,et al, 2023
Surgical Decompression for Malignant Cerebral Edema After Ischemic Stroke:Cochrane Review
Stroke 54:e500-5502, Dower,A.,et al, 2023
Endovascular Treatment for Posterior Circulation Stroke in Routine Clinical Practice: Results of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands Registry
Stroke 53:758-768, Pirson, F.A.V.,et al, 2022
Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022
Thrombectomy versus Medical Management in Mild Strokes due to Large Vessel Occlusion: Exploratory Analysis from the EXTEND-IA Trials and a Pooled International Cohort
Ann Neurol 92:364-378, Sarraj, A.,et al, 2022
Intravenous Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke
Ann Neurol 92:349-357, Tsivgoulis, G.,et al, 2022
Oral Antiplatelet Therapy for Acute Ischemic Stroke
Stroke 53:e453-e454, Minhas, J.S.,et al, 2022
Favorable Outcomes in Endovascular Therapy for Basilar-Artery Occlusion
NEJM 387:1428-1429, Schonewille, W.J.,et al, 2022
Endovascular Therapy Versus Medical Treatment for Symptomatic Intracranial Artery Stenosis
Stroke 52:e53-e54, Wang, T.,et al, 2021
Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 384:970-971, , 2021
Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Reperfusion Treatment and Stroke Outcomes in Hospitals with Telestroke Capacity
JAMA Neurol 78:527-535, Wilcock, A.D.,et al, 2021
Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion
NEJM 384:1910-1920,1954, Langezaal, L.C.M.,et al, 2021